The race for a vaccine
The race for a vaccine
Masks play a big role in the post-Covid “new normal”. However, in the absence of a masked superhero coming to our rescue, a vaccine is likely to be the only way back to the old normal. With an estimated 6% of the UK population having been exposed to the disease at the time of writing, a vaccine will be needed to reach the approximate 65% level required to achieve “herd immunity” and to finally curtail the spread of the virus. Despite improved drug efficacy, there is still no dependable cure for Covid-19.
Operation Warp Speed
The good news is that governments around the world are providing exceptional levels of investment in the search for a vaccine. The US government, for instance, has launched Operation Warp Speed, providing billions of dollars to accelerate the development and distribution of a vaccine. The plan acknowledges that some of the eight vaccines it is backing are likely to fail – but this is worth the risk if it ultimately speeds up the availability of any vaccines that do prove to be successful.
In total, there are more than 165 vaccines currently being worked on simultaneously around the world. Six of these are in late stage trials – three in China, two in the US and one in the UK. It would normally take six years to reach this stage, according to Professor Adrian Hill of Oxford University.
The mumps vaccine currently holds the title for the fastest-developed vaccine on record – and that took four years. A more recent comparison would be the five years it took to develop the Ebola inoculation, which became available at the end of 2019. This outcome was celebrated, given that vaccine development and approval can take as long as 10 to 20 years. The record looks likely to be smashed by a coronavirus vaccine, however, with genuine hopes that one may be ready for widespread distribution in early 2021. Government investment has been crucial, but technological development (including cheaper genome sequencing) and Covid-19’s similarity to other coronaviruses (such as MERS and SARS) have all helped to speed up the research process.
Record speed to human trials
Progress on a vaccine for Covid-19 has been rapid compared with other viruses, with human trials starting just 67 days after the outbreak began.
Source: CNN, World Health Organisation, National Institute of Health
The problem remains, however, that while data so far suggests the developing vaccines are “safe” (side effects have mostly been headaches, fatigue and light fever), the only reliable way to test for full vaccine efficacy and safety relies on one critical factor that no amount of emergency funding can buy: time. With clinical trials only beginning in April, not enough time has passed to conclude with enough confidence that any vaccine is fully effective or safe. Even in exceptional circumstances like we find ourselves in today, regulatory bodies are likely to require at least six months of data from late-stage studies before giving full approval to any vaccine.
Even the most promising candidates have experienced bumps on the road. UK pharmaceutical company AstraZeneca was forced to pause its trial in early September after a participant suffered a severe adverse reaction, serving to underline the importance of ensuring that all the usual safety checks are followed in order to prevent an unsafe vaccine from being rushed to market. Consequently, aside from emergency approvals for the most at-risk individuals, such as healthcare workers, regulators are unlikely to approve any vaccine for widespread distribution before the turn of the year.
Once we do have one or more approved vaccines, they need to be distributed to huge numbers of people in order to achieve herd immunity and stop the spread of the disease. This won’t be straightforward due to the complex and highly specialised process involved in vaccine manufacturing, while huge demand is going to outweigh production capacity in the immediate term. Organisations such as the Bill and Melinda Gates Foundation have donated heavily to build manufacturing capacity for the currently unproven vaccines, but other challenges will remain. For example, it is vital that any proven formula is kept stable at a low temperature, and this will naturally slow distribution in undeveloped regions and warmer climates.
Winner takes all?
With six pharmaceutical companies leading the race to develop a Covid-19 injection, the share prices of each have reacted strongly to both positive and negative reports on vaccine progress. This would imply that the successful companies stand to make significant profits on the back of their vaccine, yet in reality they have pledged to make their products available at affordable prices. The UK’s AstraZeneca has gone furthest in this regard by pledging to sell at cost-of production during the pandemic phase. This implies that successful vaccines will not significantly boost company profits in the short term. Consequently, investors should avoid making decisions in response to newsflow on vaccine development.
Of course, even in the ideal scenario, where we have one or more successful candidates that can be manufactured and distributed in the tens or hundreds of millions in the early months of 2021, this will not necessarily lead to equal distribution across all nations.
The World Health Organisation (WHO) is attempting to persuade high income nations to subsidise less developed countries via its Covax programme, trying to learn lessons from the vaccine nationalism in 2009 that they argue led to disproportionate deaths in Africa and south-east Asia during the swine flu pandemic. The Covax scheme would prioritise equal distribution by limiting participating nations to obtaining vaccines for a maximum of 20% of their populations until other nations have received their share. However, political pressures have tempted richer countries including the UK, Japan, Australia and the US into making bilateral deals to secure doses instead. It remains to be seen whether poorer countries will access a vaccine at the same time as the richest.
A majority of Americans could decline a Covid-19 vaccine
If and when a coronavirus vaccine becomes available, will you get immunised?
Source: Yahoo News/YouGov poll of 1,506 US adults, 28-30 July 2020
The final hurdle to reaching herd immunity is going to be persuading enough of the global population that a vaccine is safe and necessary.
The “vaccine-hesitant” movement has gathered steam in recent months, bolstered by concerns that political pressures from the White House ahead of the November election will obstruct the usual safety checks on vaccines. It has been further enhanced by Operation Warp Speed news flow which explains how millions of vaccines are being manufactured before full clinical trials have been completed. In an era of fake news circulating online, national health services and governments may need to deliver an effective communications campaign in order to reassure their populations that the procedures are safe, with schools, universities and employers likely playing an important role.
- Election 2020: the year in US markets
- What would be the environmental and social impact of a Biden presidency?
- Biden vs Trump: what are markets telling us?
- What’s the short-term economic impact of climate change?
- Proxy voting: how we influence corporate behaviour around the world
- Is value investing really dead?
This article is issued by Cazenove Capital which is part of the Schroders Group and a trading name of Schroder & Co. Limited, 1 London Wall Place, London EC2Y 5AU. Authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.
Nothing in this document should be deemed to constitute the provision of financial, investment or other professional advice in any way. Past performance is not a guide to future performance. The value of an investment and the income from it may go down as well as up and investors may not get back the amount originally invested.
This document may include forward-looking statements that are based upon our current opinions, expectations and projections. We undertake no obligation to update or revise any forward-looking statements. Actual results could differ materially from those anticipated in the forward-looking statements.
All data contained within this document is sourced from Cazenove Capital unless otherwise stated.